Fluoride-18F PET/CT to evaluate effectiveness of treatment of metastatic prostate cancer with Ra-223

• Grant number: 14/03317-8
• Support Opportunities: Scholarships abroad - Research
• Start date: August 01, 2014
• End date: July 31, 2015
• Field of knowledge: Health Sciences - Medicine - Medical Radiology
• Principal Investigator: Elba Cristina Sá de Camargo Etchebehere
• Grantee: Elba Cristina Sá de Camargo Etchebehere
• Host Investigator: Homer A. Macapinlac
• Host Institution: Hospital de Clínicas (HC). Universidade Estadual de Campinas (UNICAMP). Campinas , SP, Brazil
• Institution abroad: University of Texas MD Anderson Cancer Center (MD Anderson), United States

Abstract

Bone metastases from patients with prostate cancer are the greatest cause of death, reduction of quality of life and elevated treatment costs. Radium-223 dichloride or Ra223Cl2 is an alpha-emitting radioisotope (95%) of approximately 28 MeV. This radiotracer mimics calcium, which is an integral part of bone metabolism. Therapy with Ra223Cl2 (Ra-223) in patients with metastatic prostate cancer has demonstrated increased survival. However, a significant number of patients do not respond to treatment and the early identification of these patients is important to avoid inefficient and morbid therapies at elevated costs. Molecular whole-body bone imaging with 18F-fluoride PET/CT (F-18 PET/CT) is a highly sensitive method in identifying osteoblastic metastatic lesions in prostate cancer patients. Objective: Evaluate which patients most benefit from treatment with Ra-223 by using whole-body bone imaging with F-18 PET/CT. Methods: Patients with prostate cancer metastatic to bones and without visceral lesions will be submitted to treatment with Ra-223. All patients will perform F-18 PET/CT images. These images will be undertaken at 3 different time intervals: before, during and 6 months after the end of treatment with Ra-223. The clinical criteria such as pain relief, quality of life and survival (according to the form provided by the Institution) will be correlated to the F-18 PET/CT images. It is expected that F-18 PET/CT is capable of identifying which patients most benefit from this treatment. This study has not been described in the literature as of today. (AU)

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

ETCHEBEHERE, ELBA C.; ARAUJO, JOHN C.; MILTON, DENAI R.; ERWIN, WILLIAM D.; WENDT, III, RICHARD E.; SWANSTON, NANCY M.; FOX, PATRICIA; MACAPINLAC, HOMER A.; ROHREN, ERIC M.. Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT Predicts Bone Marrow Failure After 223Ra Therapy. CLINICAL NUCLEAR MEDICINE, v. 41, n. 4, p. 268-273, APR 2016. (14/03317-8)

ETCHEBEHERE, ELBA C.; MILTON, DENAI R.; ARAUJO, JOHN C.; SWANSTON, NANCY M.; MACAPINLAC, HOMER A.; ROHREN, ERIC M.. Factors affecting Ra-223 therapy: clinical experience after 532 cycles from a single institution. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, v. 43, n. 1, p. 8-20, JAN 2016. (14/03317-8)